Clear-cell carcinoma of the endometriu type I or type II endometrial carcinoma?

Purpose of Investigation: To determine if clear cell carcinoma (CCC) should be classified as a type I or type II carcinoma and provide guidance for clinical treatment. Material and Methods: This study included three groups of endometrial carcinomas: 92 cases of CCC were collected from 22 hospitals in China from January 2003 to November 2014, 272 cases of EMA were collected from Peking University People’s Hospital from February 2003 and July 2016, and 192 cases of USC were collected from 22 hospitals in China from February 2001 to December 2014. The 2009 FIGO staging system was used and information concerning clinicopathological features was collected. Results: The mean age in the CCC and USC groups was higher than that of the EMA group (p < 0.001). There was no significant difference in the FIGO Stage between the CCC and EMA groups (p = 0.158). There was no significant difference in the extent of myometrial invasion between the three groups (p = 0.064), but there was a significant difference in cervical involvement, adnexal metastasis, and lymph node metastasis (p = 0.017, p < 0.001, and p < 0.001). The patients in the CCC, EMA, and USC groups were followed up for an average of 105.6 ± 7.5 months, 135.0 ± 2.2 months, and 92.1 ± 4.4 months, respectively. Fourteen cases with CCC recurred, and 13 ended in death. There was no significant difference between the CCC and the EMA groups in recurrence and death rates (p = 0.035 > 0.0167, p = 0.018 > 0.0167, 0.0167 = 0.05/3), but the prognosis in the USC group was worse. Conclusions: CCC may follow an overlapping or a third pathway of carcinogenesis, rather than belong to the type II carcinogenesis. Therefore, if CCC should be classified as a type I or type II carcinoma is yet to be determined. Additional studies of the clinicopathological features underlying CCC will facilitate more elective management and avoid unnecessary or non-elective treatments.

Clear-cell carcinoma; Clinicopathological features; Prognosis

[1] Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., et al.,: “Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012”. Int. J.Cancer, 2015, 136, 359.

[2] Bokhman, J.V.: “Two pathogenetic types of endometrial carcinoma”. Gynecol. Oncol., 1983, 15, 10.

[3] Abeler V.M., Kjorstad K.E.: “Clear cell carcinoma of the en- dometrium: a histopathological and clinical study of 97 cases”. Gynecol. Oncol., 1991, 40, 2077.

[4] Mendivil A., Schuler K.M., Gehrig P.A.: “Non-endometrioid ade- nocarcinoma of the uterine corpus: a review of selected histological subtypes”. Cancer Control, 2009, 16, 46.

[5] Murphy K.T., Rotmensch J., Yamada S.D., Mundt A.J.: “Outcome and patterns of failure in pathologic stages I–IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy”. Int. J. Rad. Oncol. Bio. Phy., 2003, 55, 1272.

[6] Abeler V.M., Vergote I.B., Kjørstad K.E., Tropé C.G.: “Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern”. Cancer, 1996, 78, 1740.

[7] Webb G.A., Lagios M.D.: “Clear cell carcinoma of the endometrium”. Am. J. Obstet. Gynecol., 1987, 156, 1486.

[8] Jaishuen A., Kunakornporamat K., Viriyapak B., Benjapibal M., Chaopotong P., Petsuksiri J., Therasakvichya S.: “Incidence and Clinical Outcomes of Non-endometrioid Carcinoma of Endometrium: Siriraj Hospital Experience”. Asian Pac. J. Cancer Prev., 2014, 15, 2905.

[9] DeLair D.F., Burke K.A., Selenica P., Lim R.S., Scott S.N., Middha S., et al.: “The genetic landscape of endometrial clear cell carcinomas”. J. Pathol., 2017, 243, 230.

[10] Kurman R.J., Scully R.E.: “Clear cell carcinoma of the en- dometrium: an analysis of 21 cases”. Cancer, 1976, 37, 872.

[11] Benediktsdottir K.R., Jonasson J.G., Hallgrimsson J.: “Tumors in Iceland. 12. Malignant tumours of the corpus of the uterus. A histological classification, epidemiological considerations and survival”. Apmis., 1989, 97, 781.

[12] Olawaiye A.B., Boruta D.M.: “Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review”. Gynecol. Oncol., 2009, 113, 277.

[13] Abeler V.M.,Kjorstad K.E.: “Endometrial adenocarcinoma in Norway. A study of a total population”. Cancer., 1991, 67, 3093.

[14] Glasspool R.M., McNeish I.A.: “Clear cell carcinoma of ovary and uterus”. Curr. Oncol. Rep., 2013, 15, 566.

[15] Kulhan M., Kulhan G., Nayki U., Nayki C., Ulug P., Sipahi M., et al.: “Assessment of clinicopathological features, evaluation of treatment, and prognosis of clear cell and serous papillary endometrial carcinoma”. Ginekol. Pol., 2016, 87, 570.

[16] Prueksaritanond N., Chantape W.: “Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital”. J. Med. Assoc. Thai., 2016, 99, S75.

[17] Abdulfatah E., Sakr S., Thomas S., Al-Wahab Z., Mutch DG., Dowdy S., et al.: “Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in a Multi-institutional Cohort of 165 Cases”. Int. J. Gynecol. Cancer, 2017, 27, 1714.

[18] Ju B., Wang J., Yang B., Sun L., Guo Y., Hao Q.: “Morphologic and Immunohistochemical Study of Clear Cell Carcinoma of the Uterine Endometrium and Cervix in Comparison to Ovarian Clear Cell Carcinoma”. Int. J. Gynecol. Pathol., 2018, 37, 388.

[19] Moriya T., Kanomata N.: “Pathology of endometrial carcinoma”. 2014. 46.

[20] Bae H.S., Kim H., Young Kwon S., Kim K.R., Song J.Y., Kim I.: “Should endometrial clear cell carcinoma be classified as Type II endometrial carcinoma”? Int. J. Gynecol. Pathol., 2015, 34, 74.

[21] Yasuda M.: “Immunohistochemical characterization of endometrial carcinomas: endometrioid, serous and clear cell adenocarcinomas in association with genetic analysis”. J. Obstet. Gynaecol. Res., 2014, 40, 2167.

[22] Smith R.S., Kapp D.S., Chen Q., Teng N.N.: “Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy”. Int. J. Radiat. Oncol. Biol. Phys., 2000, 48, 767.

[23] Giri P.G., Schneider V., Belgrad R.: “Clear cell carcinoma of the endometrium: an uncommon entity with a favorable prognosis”. Int. J. Radiat. Oncol. Biol. Phys., 1981, 7, 1383.

[24] Murphy K.T., Rotmensch J., Yamada S.D., Mundt A.J. “Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy”. Int. J. Radiat. Oncol. Biol. Phys., 2003, 55,1272.